Erik Dosedla, Daniel Kelij, Ján Richnavský, Štefan Lukačín, Sergiu Leahomschi, Pavel Calda
Hypertension in pregnancy does not always lead to preeclampsia. Management of hypertension in pregnancy is difficult
and also costly because of the lack of a differential diagnostic biomarker predicting the development of preeclampsia.
A biomarker which could predict the clinical onset of the severe pathology of preeclampsia would be very useful. Several
multicentric prospective studies have demonstrated that the cytokines involved in angiogenesis potentially may be
used as biomarkers to predict preeclampsia, using precisely automated immunoassays. The results of studies of these
immunoassays indicate that they have a negative predictive value, making it possible to rule out the development of
preeclampsia for at least one week. This review article also includes etiopathogenesis of preeclampsia, risk factors, clinical
signs, screening as well as options for the treatment of preeclampsia. Prediction, prevention and early diagnosis
and adequate treatment of preeclampsia are important tasks of modern obstetrics.